John F. Seymour, MBBS, PhD | Authors


Acalabrutinib Shows Better Exposure-Adjusted Tolerability in R/R CLL

June 02, 2022

John F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.